Silence Therapeutics Plc, a company that has moved quickly to capitalise on the new science of ribonucleic acid interference (RNAi), has announced plans to merge with the privately-owned Intradigm Corp of the US, which is in the same business.
Merck Serono has entered into a research collaboration in multiple sclerosis with the Brigham and Women’s Hospital in Boston, Mass, US, aimed at identifying new biomarkers and possible drug targets. Financial details were not disclosed.
Galápagos NV said that it has expanded its collaboration with GlaxoSmithKline to discover new drugs for multiple indications in the field of arthritis. The two companies are exploring drugs directed at the kinase target GT622.
Addex Pharmaceuticals Ltd said that it is ending development of its negative allosteric modulator, ADX10059, for chronic indications including long-term treatment of gastroesophageal reflux disease (GERD) and migraine prophylaxis.
Cancer Research UK has reported that an experimental radioactive cancer therapy showed clinical benefit in a Phase 1 study of patients with Hodgkin’s lymphoma. The study was published in the journal Clinical Cancer Research on 15 December 2009.
Evolva SA of Switzerland has raised an additional CHF 21 million (€13.9 million) to finance its takeover of Arpida Ltd, creating a new publicly-listed company with a technology platform that uses synthetic biology to create new small molecule drugs.
MediGene AG has reported a delay of about six months in the start of a planned Phase 3 trial of its drug candidate for pancreatic cancer, EndoTAG-1. The German company has also reduced the size of its executive board to two persons.
GlaxoSmithKline has agreed to pay €33.6 million upfront and to make an equity investment of up to €84 million in Intercell AG in order to gain access to the Austrian company’s needle-free, patch-based vaccine technology.
Europe’s IPO market reopens. After remaining dormant since early 2008, the European market for initial public offerings (IPOs) of biotech companies has reopened with a
Neovacs SA of France has initiated a Phase 2a study of its tumour necrosis factor alpha (TNF alpha) kinoid immunotherapy in patients with rheumatoid arthritis.